Fibrates: where are we now?

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Cardiovascular disease is a leading global cause of mortality.
• Dyslipidemia significantly increases cardiovascular disease risk.
• Effective dyslipidemia management is crucial for cardiovascular disease prevention.

Purpose of the Study:

• To review dyslipidemia treatment using fibrate therapy.
• To contrast fibrate therapy with statin therapy and combination therapy.
• To evaluate the efficacy and safety of different lipid-lowering strategies.

Main Methods:

• Systematic review of studies identified through Medline and Cochrane Library.
• Focus on studies discussing fibrates, statins, and combined therapy.
• Quality assessment of selected studies based on methodology, results, and data.

Main Results:

• Combination fibrate and statin therapy can be more effective than monotherapy in achieving optimal lipid levels.
• Combined therapy demonstrated effectiveness without significant side effects, provided gemfibrozil is not used.
• Quality assessment confirmed the scientific evidence supporting these findings.

Conclusions:

• Combination therapy, excluding gemfibrozil, offers superior lipid management for cardiovascular disease risk.
• Fibrates play a key role in targeting specific lipid abnormalities.
• Further research supports optimized combination therapies for dyslipidemia.